GLP-1 Drugs Show Modest Weight Loss Benefit in PCOS — Evidence for Other Outcomes Remains Uncertain
Meta-analysis of 11 RCTs found GLP-1 drugs reduce BMI by 1.38 kg/m² in PCOS women, but evidence for metabolic, reproductive, or psychological benefits remains low certainty.
Quick Facts
What This Study Found
GLP-1 RAs as add-on therapy reduced BMI by -1.38 kg/m² (95% CI -2.39 to -0.38; low certainty) in PCOS women. No significant differences for LDL, triglycerides. Insufficient evidence for glucose, insulin, hirsutism, menstrual regularity.
Key Numbers
How They Did This
Systematic review and meta-analysis of 11 RCTs from Cochrane, EMBASE, and Medline (searched September 2024), registered in PROSPERO CRD42024535096.
Why This Research Matters
PCOS is the most common endocrine disorder in reproductive-age women. Understanding what GLP-1 drugs can and cannot do for PCOS guides clinical decision-making.
The Bigger Picture
Despite enormous enthusiasm for GLP-1 drugs, their proven benefits in PCOS are limited to modest weight loss. The field needs better-designed trials with PCOS-specific outcomes.
What This Study Doesn't Tell Us
Low certainty evidence overall. Most trials were short-term. No assessment of quality of life or reproductive outcomes in sufficient numbers. Heterogeneity in study designs.
Questions This Raises
- ?Would higher GLP-1 doses or newer agents (tirzepatide) show reproductive benefits in PCOS?
- ?Should PCOS-specific clinical trials be designed with reproductive and hormonal primary endpoints?
- ?Could combining GLP-1 drugs with metformin or OCP improve PCOS outcomes?
Trust & Context
- Key Stat:
- -1.38 kg/m² BMI Modest but significant weight reduction as add-on GLP-1 therapy in PCOS, though reproductive and metabolic benefits unproven
- Evidence Grade:
- Systematic review of RCTs with GRADE assessment. Low certainty evidence limits confidence in conclusions.
- Study Age:
- Published in 2025.
- Original Title:
- GLP-1 receptor agonist treatment in women with polycystic ovary syndrome - a systematic review and meta-analysis.
- Published In:
- European journal of endocrinology (2026)
- Authors:
- Forslund, Maria, Wändell, Per, Forsberg, Lisa, Österberg, Marie, Dagerhamn, Jessica, Wernersson, Emma, Kärrman Fredriksson, Maja, Ringborg, Anna, Lindén Hirschberg, Angelica
- Database ID:
- RPEP-15170
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs help with PCOS?
They can help with weight loss (about 1.4 kg/m² BMI reduction), but there is not yet enough evidence to know if they improve other PCOS symptoms like irregular periods, excess hair growth, or hormone levels.
Should women with PCOS take Ozempic?
GLP-1 drugs may be considered for weight management in PCOS with obesity, but they should not be expected to treat PCOS-specific symptoms based on current evidence. Better trials are needed.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15170APA
Forslund, Maria; Wändell, Per; Forsberg, Lisa; Österberg, Marie; Dagerhamn, Jessica; Wernersson, Emma; Kärrman Fredriksson, Maja; Ringborg, Anna; Lindén Hirschberg, Angelica. (2026). GLP-1 receptor agonist treatment in women with polycystic ovary syndrome - a systematic review and meta-analysis.. European journal of endocrinology. https://doi.org/10.1093/ejendo/lvag033
MLA
Forslund, Maria, et al. "GLP-1 receptor agonist treatment in women with polycystic ovary syndrome - a systematic review and meta-analysis.." European journal of endocrinology, 2026. https://doi.org/10.1093/ejendo/lvag033
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 receptor agonist treatment in women with polycystic ov..." RPEP-15170. Retrieved from https://rethinkpeptides.com/research/forslund-2026-glp1-receptor-agonist-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.